Bind Therapeutics and Roche collaborate


Roche (RHHBY) signs a research agreement with Bind Therapeutics (BIND) to discover novel nanomedicines in therapeutic areas outside of oncology using Bind's Accurins technology. The focus for the research is combining Accurins with Roche's proprietary therapeutic payloads and targeting ligands.

Financial terms are not disclosed.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs